Recent News Releases

Thursday 30 October, Riyadh – CSL Seqirus and Vaccine Industrial Company, have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology...

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The University...

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA, Oct....

INTENDED FOR MEDIA AND BUSINESS INVESTORS ONLY Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable...

Summit, New Jersey, USA | 17 October 2025 – CSL Seqirus, a business of CSL (ASX:CSL) today announced that it will be presenting 14 abstracts at the European Scientific Working group on Influenza...

Melbourne, Australia – CSL has announced that the Science Based Targets initiative (SBTi) has approved CSL’s near-term science-based emissions reduction targets. These are:...

CSL Behring Canada Inc., a business unit of global biopharma leader CSL, today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the...

FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor...

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit...

Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit...

ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and...

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically...

CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 category....

CSL Seqirus to provide pandemic influenza vaccine to support 17 EU and EEA countries and the EU Commission in the event of a pandemic declaration. The decision by the Health Emergency Preparedness...

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive...

ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the first-in-class...

To date, there have been over 46,300 lab-confirmed influenza cases in Australia, more than 50% higher than the previous record of flu cases in Australia during the first quarter (January – March...

Melbourne, 2 April 2025 – Australian healthcare company CSL has launched the CSL Community Impact Awards, a new initiative designed to support not-for-profit community organisations focused on...

Melbourne, 4 March 2025 – CSL Seqirus and Esperion Therapeutics have today announced the signing of an exclusive license and distribution agreement to commercialize Nexletol® (bempedoic acid)...

ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ANDEMBRY,...

ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation...

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional...

- ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading...

94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal...

Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment...

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years...

MELBOURNE – 24 October 2024 – Two scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are developing...

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024...

Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL...

As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For the...

Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan

Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®,...

CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...

Throughout 2023 and 2024, outbreaks of highly pathogenic avian influenza (HPAI) viruses among birds have been reported in several regions including Africa, Asia, Europe, and North America...

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior...

Under the licensing and distribution agreement, CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialisation of neffyTM (adrenaline nasal spray) ARS...

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically...

Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility at an event officiated by Lord Mayor, Sally Capp AO.

CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of...

CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year...

March 7, 2024 During the latter part of 2023 and following notification by the World Health Organization that B/Yamagata lineage viruses have not been confirmed as detected in circulation since...

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe...

Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS4 Revenue $8.05 billion, up 11% at CC3 NPAT $1.90 billion1, up 17% NPAT $1.94 billion1 at CC3, up 20% NPATA $2.02 billion1,2 ,...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...

The FDA has been notified of the incident, which occurred at a plasma donation center

Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain...

Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024...

CSL's HEMGENIX® is a one-time, single-dose treatment for male adults with severe/moderately severe hemophilia B BERN, Switzerland, Jan. 15, 2024 /PRNewswire/ -- Global biotechnology leader CSL...

- Hizentra® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic...

- 4- and 5-gram ZEMAIRA® vials may reduce the number of vials necessary for reconstitution, thereby providing convenience and lowering package waste KING OF PRUSSIA, Pa., Jan. 2, 2024...

Study conducted by Meiji Seika Pharma in Japan Data follow approval of the world's first self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine for adults by Japan Ministry of Health, Labor and...

These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has...

HEMGENIX® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years...

Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's...

Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of...

HEMGENIX®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass., Oct. 27, 2023...

Global biotechnology leader CSL (ASX: CSL) today announced that Health Canada has authorized HEMGENIX® (etranacogene dezaparvovec), the first and only gene therapy for the treatment of hemophilia...

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) announced today that it has signed a Renewable-Linked Power Purchase Agreement (PPA) with Australian energy provider, AGL. AGL was awarded...

MELBOURNE – 12 October 2023 – Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are each developing new kinds of...

MELBOURNE, AUSTRALIA – 04 October 2023 – CSL’s Research Acceleration Initiative (RAI) continues to expand its reach with seven medical researchers awarded new RAI partnerships, including up...

CSL Seqirus will provide its registered pandemic influenza vaccine to the UK if an influenza pandemic occurs during the next four years. This new agreement to CSL Seqirus follows more than ten...

CSL Seqirus presents new data at the 9th ESWI meeting on the impact of effective vaccination campaigns to protect healthcare systems across the world.1,2 The French data highlights how vaccines...

SUMMIT, N.J., September 15, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today announced new data that will be presented at the European Scientific Working Group on Influenza (ESWI)...

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response...

The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject®...

Melbourne, Australia – 21 August 2023 – Australia today ushered in a new era in scientific and medical innovation, with Prime Minister of Australia, Anthony Albanese officially opening CSL’s...

Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple disciplines and functions, has been appointed Chief...

CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 pandemic, there has been a...

HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus...

Injectafer® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement in exercise capacity in adult patients with...

Melbourne, Monday 22 May CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping...

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus...

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with...

Hizentra® is the first and only immune globulin (Ig) available in prefilled syringes, offering those living with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy...

The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology...

Melbourne, 1 March 2023 CSL Seqirus (Seqirus Pty Ltd) and Amarin Corporation plc (NASDAQ:AMRN) have today announced the signing of an exclusive license and distribution agreement to commercialise...

Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema KING OF PRUSSIA, Pa., March 1, 2023...

Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions...

Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates...

CSL recognized in Forbes and Statista's Best Large-sized Employer category for the fourth time since 2018. KING OF PRUSSIA, Pa., Feb. 21, 2023 /PRNewswire/ -- Global biotechnology leader CSL has...

HEMGENIX® underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead full lives MARBURG, Germany, Feb. 20, 2023 /PRNewswire/ -- Global...

First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease

Global biotechnology leader CSL (ASX: CSL) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) of etranacogene dezaparvovec.

Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a "Vifor Share").

Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from 6 March 2023 MELBOURNE, Australia, Dec. 12, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited...

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens...

Long-term data from the pivotal HOPE-B study show a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding 24-month results...

China has the world’s largest iron deficiency anemia population with estimated prevalence of 15%1 Approval may also benefit the Chinese healthcare system, among others through implementation of...

Iron Deficiency Day unites a strong international coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the focus is on importance of...

Global biotechnology leader CSL (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B.

CSL, WEHI, and the University of Melbourne today announced the appointment of an independent operator to oversee and manage the new start-up incubator which will support and grow early-stage Australian biotech companies, providing both lab and office spaces.

Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in...

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced thrombus dissolving drug candidate, TS23.

Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor Pharma AG's ad hoc announcement of August 2, 2022).

Global biotechnology leader CSL’s new global corporate headquarters has been awarded a five-star rating from the Green Building Council of Australia.

Global biotherapeutics leader CSL today announced that two Australian scientists have each been awarded a CSL Centenary Fellowship of $1.25 million over five years.

Vifor Pharma AG (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's registered shares.